Welcome : Guest

Government Funded Initiatives to Reduce Infant Mortality Rates Drives the Global Pediatric Drugs and Vaccines Market

Published: June 2017


  • Code: MCP-6503
  • Pages: 431
  • Tables: 128
  • Companies: 90


The global market for Pediatric Drugs and Vaccines is forecast to reach US$143.2 billion by 2024, spurred by continued government efforts especially in developing countries to reduce infant mortality and the resulting expansion of diseases covered under national immunization programs. The market also stands to benefit from rising early-onset of diseases and health conditions such as obesity and hypertension; and strong developments in medical research and the resulting development of prevention strategies for numerous childhood diseases and illness. The United States represents the largest market worldwide, supported by the country’s focus on raising healthy children and regulations that promote new drug development. Asia-Pacific ranks as the fastest growing market with a CAGR of 11.3% over the analysis period, driven by the large pediatric population; changing lifestyle and environmental factors and the resulting increase in ailments such as ADHD; high prevalence of malaria, and other parasitic infections which are endemic to tropical Asian climate; and globalization of drug development and gradual increase in the capability of Asian companies to research, develop and manufacture pediatric agents. 

    Summary of Findings

  • Innovation in Drug Development for High Burden Pediatric Diseases such as Asthma, Anorexia, Growth Deficiencies, Birth Defects, Juvenile Diabetes, Attention Deficit Hyperactivity Disorder and Cancer to Benefit Growth
  • Preference for Combination Vaccines Over Single Vaccine Drives Growth in the Pediatric Vaccines Market
  • Continued High Prevalence of Pneumonia Makes Pneumococcal Vaccines a Large Market With Companies such as GlaxoSmithKline Ranking Among the Leading Manufacturers
  • WHO and UNICEF Child Healthcare Programs Provide the Foundation for the Growth of Pediatric Vaccines
  • Launch of Orphan Drug Designation Programs Encourage Drug Development for Rare Diseases and Conditions

    Timeline for Analysis

  • Market Estimates and Forecasts for 2016-2024
  • Historic Review 2011-2015

    Geographic Markets Analyzed

  • US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Latin America, and Rest of World

    Market Segmentation & Classification

  • Therapeutic Class:
    • Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs
  • Type:
    • Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Others


  • Abbott Laboratories
  • Allergan, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company


  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable

Interested in our research, you can contact our 24/7 Research Support e-Desk at rsd@strategyr.com